Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Pros and Cons of Portal Vein Embolization With Hematopoietic Stem Cells Application in Colorectal Liver Metastases Surgery

V. Treska, J. Bruha, V. Liska, J. Fichtl, K. Prochazkova, T. Petrakova, P. Hosek

. 2020 ; 34 (5) : 2919-2925. [pub] -

Jazyk angličtina Země Řecko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc21020185

BACKGROUND/AIM: Portal vein embolization (PVE) with autologous stem cells application (aHSC) is a method for future liver remnant volume (FLRV) increase. The aim of the study was to evaluate the positivite and negativite aspects of the method in clinical practice. PATIENTS AND METHODS: PVE with aHSC application was used in 32 patients with colorectal liver metastases and insufficient FLRV. Preoperative number of colorectal liver metastases (CLMs) was 5.2±3.6, CLMs volume 70.1±102.3 mm3 Results: FLRV growth occurred after 2-3 weeks in 31 (96.9%) patients, with volume increase from 528.2±170.5 to 715.4±143.3 ml (p=0.0001). Postoperative thirty days mortality, morbidity was 0% and 3.1%, respectively. Insufficient FLRV growth occurred in one patient. R0 liver resection was performed in 27(87.1%) patients. CLMs volume progression was in 5 (15.6%) patients from 680.0±59.4 to 723.1±57.1 ml (p=0.01). One and two-year overall survival were 88% and 62.9% respectively. Six and twelve-month recurrence-free survival rates were 50.7% and 39.6% respectively. CONCLUSION: PVE with aHSC application is a safe and useful method for FLRV growth. It significantly increases secondary CLMs resectability. However, it can cause CLMs progression. Liver resection should, therefore, be performed as soon as possible after achieving optimal increase of FLRV.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21020185
003      
CZ-PrNML
005      
20210830101818.0
007      
ta
008      
210728s2020 gr f 000 0|eng||
009      
AR
024    7_
$a 10.21873/invivo.12121 $2 doi
035    __
$a (PubMed)32871833
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a gr
100    1_
$a Treska, Vladislav $u Department of Surgery, School of Medicine, University Hospital in Pilsen, Pilsen, Czech Republic treska@fnplzen.cz
245    10
$a Pros and Cons of Portal Vein Embolization With Hematopoietic Stem Cells Application in Colorectal Liver Metastases Surgery / $c V. Treska, J. Bruha, V. Liska, J. Fichtl, K. Prochazkova, T. Petrakova, P. Hosek
520    9_
$a BACKGROUND/AIM: Portal vein embolization (PVE) with autologous stem cells application (aHSC) is a method for future liver remnant volume (FLRV) increase. The aim of the study was to evaluate the positivite and negativite aspects of the method in clinical practice. PATIENTS AND METHODS: PVE with aHSC application was used in 32 patients with colorectal liver metastases and insufficient FLRV. Preoperative number of colorectal liver metastases (CLMs) was 5.2±3.6, CLMs volume 70.1±102.3 mm3 Results: FLRV growth occurred after 2-3 weeks in 31 (96.9%) patients, with volume increase from 528.2±170.5 to 715.4±143.3 ml (p=0.0001). Postoperative thirty days mortality, morbidity was 0% and 3.1%, respectively. Insufficient FLRV growth occurred in one patient. R0 liver resection was performed in 27(87.1%) patients. CLMs volume progression was in 5 (15.6%) patients from 680.0±59.4 to 723.1±57.1 ml (p=0.01). One and two-year overall survival were 88% and 62.9% respectively. Six and twelve-month recurrence-free survival rates were 50.7% and 39.6% respectively. CONCLUSION: PVE with aHSC application is a safe and useful method for FLRV growth. It significantly increases secondary CLMs resectability. However, it can cause CLMs progression. Liver resection should, therefore, be performed as soon as possible after achieving optimal increase of FLRV.
650    12
$a kolorektální nádory $7 D015179
650    12
$a terapeutická embolizace $x škodlivé účinky $7 D004621
650    _2
$a hematopoetické kmenové buňky $7 D006412
650    _2
$a hepatektomie $x škodlivé účinky $7 D006498
650    _2
$a lidé $7 D006801
650    12
$a nádory jater $x chirurgie $7 D008113
650    _2
$a vena portae $x chirurgie $7 D011169
650    _2
$a předoperační péče $7 D011300
655    _2
$a časopisecké články $7 D016428
700    1_
$a Bruha, Jan $u Department of Surgery, School of Medicine, University Hospital in Pilsen, Pilsen, Czech Republic
700    1_
$a Liska, Vaclav $u Department of Surgery, School of Medicine, University Hospital in Pilsen, Pilsen, Czech Republic
700    1_
$a Fichtl, Jakub $u Department of Surgery, School of Medicine, University Hospital in Pilsen, Pilsen, Czech Republic
700    1_
$a Prochazkova, Kristyna $u Department of Surgery, School of Medicine, University Hospital in Pilsen, Pilsen, Czech Republic
700    1_
$a Petrakova, Tereza $u Department of Surgery, School of Medicine, University Hospital in Pilsen, Pilsen, Czech Republic
700    1_
$a Hosek, Petr $u Biomedical Centre, School of Medicine, Pilsen, Czech Republic
773    0_
$w MED00175831 $t In vivo (Athens, Greece) $x 1791-7549 $g Roč. 34, č. 5 (2020), s. 2919-2925
856    41
$u https://pubmed.ncbi.nlm.nih.gov/32871833 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20210728 $b ABA008
991    __
$a 20210830101819 $b ABA008
999    __
$a ok $b bmc $g 1690888 $s 1140631
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 34 $c 5 $d 2919-2925 $e - $i 1791-7549 $m In Vivo $n In Vivo $x MED00175831
LZP    __
$a Pubmed-20210728

Najít záznam

Citační ukazatele

Možnosti archivace